The Short Answer At Least For One Vaccine Is Sometime Between Now And January 2022
When will the COVID-19 vaccines get full Food and Drug Administration approval?
Thats a question on a lot of minds as the daily number of COVID-19 cases rise across the U.S., driven by a more contagious mutation of the coronavirus. More public and private institutions are considering or imposing vaccine mandates;on their employees. And some, including the Department of Defense,;say;they will consider requiring employees be vaccinated once the Food and Drug Administration gives the vaccines final approval.
When will that happen? The short answer at least for one vaccine is sometime between now and January 2022.
Pfizer and BioNTech, which developed one of the three COVID-19 vaccines available in the U.S., in May;completed their application;for full FDA approval for use in people ages 16 and older. They are the only companies to have completed an approval application so far. The FDA is giving the application priority review, which expedites the process by a few months, with a decision deadline of January 2022. But the agency says it expects to have a decision before January.
Moderna;said;in June that it had begun submitting parts of its application. Johnson & Johnson has not yet submitted an application, but plans to this year.
The FDA requires even more information from the manufacturers before it grants full approval.
Whats the holdup?
Heres what we know about where the process stands.
Who Would Be Eligible To Get A Vaccine Booster Shot
In August, health officials in the Biden administration recommended an additional shot for Americans 18 and over who are fully vaccinated with the Pfizer or Moderna shots, proposing a booster eight months after being fully vaccinated.;
Waiting months in between doses allows the immune system to develop a full response before it is helped by a boost. Whatever the time gap, the booster plan would need to be evaluated and approved by government scientists.
“We believe that that third dose will ultimately be needed to provide the fullest and continual extent of protection that we think people need from the virus,” Murthy said. “Our plan is to stay ahead of this virus by being prepared to offer COVID-19 booster shots to fully vaccinated adults 18 years and older.”;
Murthy said the FDA will evaluate booster shots for those younger than 18 years of age, and the administration will follow FDA recommendations for minors.
Do Americans Think This Will Change Minds
- Folks who don’t want the vaccine are going to convince themselves not to get it one way or another, which is why the Biden administration has to be as consistent as possible with their mandates and information. – Greg Samuel, 33, Washington DC
- Maybe 50% of people who haven’t been vaccinated have said they’d prefer an FDA approval. So with the approval, what’s the excuse? I’m hopeful the seal of approval will give them confidence. I’m optimistic, but I don’t think it’s going to change too much. – Dr Mireya Wessolossky, 58, Massachusetts
- I would still like to see how it affects people in the next few years before getting vaccinated. This vaccine has only been out for less than a year. – Jenson Bland, 21, Georgia
You May Like: Is Being Dizzy A Sign Of Covid
Why Is The Process Taking So Long
It takes the agency at least six months, if not longer, to review all the supporting documentation related to an application to reach a decision. As you might expect, clinical trial data is scrutinized, but the process involves more than just experts reading data. The FDA also inspects manufacturing facilities and meets many times with company executives. Despite the time and labor intensive process, some experts say the agency is moving too slowly. Ashish Jha, dean of the Brown University School of Public Health, called on the FDA to pick up the pace on Good Morning America last week. “I think a lot of us are baffled why the FDA is taking so long,” he said.;
Unfortunately, approving the vaccines isnt just about science and evidence the FDA also has political hurdles to overcome. Last year, former President Trump criticized the agency over its request that vaccine developers submit at least two months of safety data for emergency use. He also accused the agency numerous times of conspiring against him in the 2020 presidential election. This political interference sowed public doubt in some conservative circles, as people questioned the tactics of the normally science-focused agency.;
I think the FDA realizes whats at stake here and theyre working round the clock to do it.;
Paul Offit, director of Vaccine Education Center at Children’s Hospital of Philadelphia
Why Should I Get A Covid
When you get a COVID-19 vaccine, you are choosing to protect yourself and make a difference for your children, parents, grandparents, and other loved ones. Millions of people in the U.S. have already received a COVID-19 vaccine. For a community to be fully protected, most community members need to get the vaccine. Getting vaccinated to prevent COVID-19 will help protect you from COVID-19, and it may also protect the people around you.
Don’t Miss: What Oxygen Level Is Too Low Covid
Approval Of The Pfizer
The full federal approval on Monday of a coronavirus vaccine for people 16 and older appeared to clear the way for local officials, private businesses and others who want to impose vaccine requirements to do so in some states that have banned them.
At least three states that banned vaccine requirements by law or executive order Montana, Texas and Utah did so specifically because the three vaccines in use in the United States were being administered under emergency-use authorizations, not full approval.
Now one of the vaccines has that approval, undercutting that justification and potentially setting the stage for more of the kind of legal battles that have erupted around the country over the bans, often pitting cities, counties or school districts that want stricter vaccine requirements against governors who say they want to protect individual freedom.
The issue has grown more urgent as the pace of vaccination has slowed and as new cases, hospitalizations and deaths have risen sharply, driven largely by the highly contagious Delta variant. Many states that have banned vaccine requirements also have relatively low vaccination rates and are struggling with the latest surge in infections.
In Texas, Gov. Greg Abbott issued an executive order that took effect in July, stating that no governmental entity can compel any individual to receive a Covid-19 vaccine administered under an emergency use authorization.
Moderna Begins Filing For Fda Approval Of Covid
Since Modernas vaccine was granted the Fast Track designation last year, theyre able to submit sections of the application as they are completed called a rolling review rather than all at once. This helps lower the applications review time.;
Once the BLA submission is complete, the FDA will notify them when its been accepted for review.
Recommended Reading: How Do You Catch Covid
Learn More About Covid
Learn about the evidence supporting FDA-approval of Comirnaty and FDA emergency use authorization of COVID-19 vaccines
FDA approves Comirnaty , which was previously known as Pfizer-BioNTech COVID-19 Vaccine, for the prevention of COVID-19 disease in individuals 16 years of age and older.
The U.S. Food and Drug Administration approved Comirnaty for the prevention of COVID-19 caused by SARS-CoV-2 in individuals 16 years of age and older. The vaccine has the same formulation as the Pfizer-BioNTech COVID-19 Vaccine that continues to be available under emergency use authorization , including for individuals 12 through 15 years of age, and for the administration of a third dose in certain immunocompromised individuals.
- Frequently asked questions
Emergency use authorization allows these vaccines to be distributed in the U.S. Learn more about EUAs for COVID-19 vaccines from the FDAs Center for Biologics Evaluation and Research .
What Safety Information Is Available About Covid
The FDA evaluated data from clinical studies that included tens of thousands of people for Comirnaty, the FDA-approved COVID-19 vaccine, and for each of the COVID-19 vaccines authorized for emergency use.;
The FDA has authorized three vaccines for emergency use because the data from ;clinical studies clearly showed that the known and potential benefits of the FDA-authorized COVID-19 vaccines outweighed the known and potential risks.;
Approved COVID-19 Vaccine
The data to support the decision to approve Comirnaty builds on extensive data and information that supported the Pfizer-BioNTech COVID-19 Vaccine EUA , including information about the vaccines safety and effectiveness. The safety of Comirnaty was evaluated in individuals 16 years of age and older, approximately 22,000 of whom received the vaccine and 22,000 of whom received placebo. More than half of the clinical trial participants were followed for safety follow-up for at least four months after the second dose. ;After issuance of the EUA, clinical trial participants were unblinded in a phased manner over a period of months to offer placebo recipients the Pfizer-BioNTech COVID-19 Vaccine. ;Overall, in blinded and unblinded follow-up, approximately 12,000 vaccine recipients have been followed for at least 6 months.
Myocarditis and Pericarditis Following Vaccination with Comirnaty, Moderna and Pfizer-BioNTech COVID-19 Vaccines
Guillain Barré Syndrome Following Vaccination with Janssen COVID-19 Vaccine
Don’t Miss: How Often Do You Need The Covid Vaccine
What Does Fda Approval Add
FDA approval is based on review of a biologics license application, the standard mechanism for the review of novel drugs and vaccines. The product must be demonstrated to be safe, pure and potent. For coronavirus vaccines, this means completion of well-conducted clinical trials with six months of followup as well as review of the manufacturing process.
For the Pfizer-BioNTech vaccine, the FDA reviewed 340,000 pages of data supporting the vaccines safety and efficacy about three times the amount of data contained in the application for emergency use. Additionally, the FDA inspected manufacturing facilities and negotiated the labelling information.
The FDAs approval of the vaccine will likely affect unvaccinated people, organizations, doctors and the pharmaceutical industry.
What’s The Controversy With The Who Over Booster Shots
The plan for boosters has resulted in a;backlash among countries;that are struggling to deliver first and second shots to residents.;
Last month, World Health Organization Director-General Tedros Adhanom Ghebreyesus;;on booster shots in high-income countries, citing the global disparity in vaccine distribution. Of the 4 billion doses administered globally, 80% have gone to high- and upper-middle income countries that make up less than half the world’s population, he said. He also called on vaccine producers to prioritize Covax, the world’s COVID-19 vaccine;distribution program.
At a Sept. 8;news conference, Tedros said that the world’s poor shouldn’t have to be satisfied with leftovers. “Because manufacturers have prioritized or been legally obliged to fulfill bilateral deals with rich countries willing to pay top dollar, low-income countries have been deprived of the tools to protect their people,” he said.
White House Press Secretary Jen Psaki said on Aug. 17 that the US will have enough vaccines to both provide boosters for those who are fully vaccinated in the US and meet the global demand. “We have long planned from enough supply,” she said.;
You May Like: Does China Have A Vaccine For Covid
Full Approval Requires Long
For vaccines, the FDA grants emergency use authorizations after it reviews at least two months of follow-up results for clinical trial participants who received the actual injection. For full approval, known in FDA-speak as a biologics license application, the agency wants to see six months of data to ensure there are no widespread problems or to detect adverse reactions. Both reviews examine safety and efficacy while also studying what the optimal distribution strategy might be.
With vaccines in general, almost all complications that occur tend to happen shortly after the vaccine is administered, often within a day or two. Most side effects of the Covid-19 vaccines in the US tend to be mild or moderate, ranging from pain at the injection site to fatigue to fever. A very small number of recipients reported severe allergic reactions shortly after their shots, which is why most vaccine clinics have a waiting period where they can monitor patients for 15 to 30 minutes.
Monitoring clinical trial participants over six months also yields more information about how long protection from the vaccine lasts and whether any subsets of the population are more vulnerable. And it presents an opportunity to see how well the vaccines hold up against variants that were not widely circulating earlier in the pandemic.
Pfizer Becomes First Covid Vaccine To Gain Full Fda Approval
Pfizer’s two-dose Covid-19 vaccine has received full approval from the US Food and Drug Administration – the first jab to be licensed in the nation.
The vaccine had initially been given emergency use authorisation. Its two jabs, three weeks apart, are now fully approved for those aged 16 and older.
The approval is expected to set off more vaccine mandates by employers and organisations across the country.
It comes amid lingering vaccine hesitancy among many Americans.
In a statement, the FDA said its review for approval included data from approximately 44,000 people. The vaccine, which will now be marketed as Comirnaty, was found to be 91% effective in preventing Covid disease.
Acting FDA commissioner Janet Woodcock said that the public “can be very confident” the vaccine meets high safety, effectiveness and manufacturing quality standards.
It still has emergency use authorisation for children aged 12 to 15.
Following the announcement, the US military said they would officially require all 1.3m active duty US troops to get vaccinated.
The jabs are being provided at no cost to Americans.
The FDA initially gave Pfizer temporary authorisation – a clearance given if the agency determines the benefits of a product outweigh potential risks during a public health emergency.
Also Check: When Was Covid 19 Declared A Pandemic
Full Approval: What Does Fda Approval For The Pfizer Covid
Dr. Chris Beyrer is the Desmond M. Tutu Professor in Public Health and Human Rights at the Johns Hopkins Bloomberg School of Public Health. An infectious diseases epidemiologist, he currently serves as Senior Scientific Liaison to the COVID-19 Vaccine Prevention Network, the Co-VPN, for Community Engagement. He is a Professor of Epidemiology and Medicine at Johns Hopkins.
- Pfizer-BioNTechâs mRNA COVID-19 vaccine has now received full FDA approval for those aged 16 and over; it continues to have emergency use authorization for those aged 12 to 15.
- Full FDA approval has led some entities, including the U.S. Military, to mandate COVID-19 immunization.
- While the rate of immunization has increased following full FDA approval of Pfizerâs vaccine, we still need higher numbers of Americans to be immunized at a faster pace to get ahead of Delta and other emerging variants.
Since the full approval of the vaccine, and the start of vaccine mandates across multiple sectors, immunization rates are increasing again, but the science shows clearly that we need higher numbers of Americans to be immunized. And, we need a faster rate of immunization to get ahead of Delta and other emerging variants. Both pace and coverage matter.
Chris Beyrer, Desmond Tutu Professor in Public Health and Human Rights
Johns Hopkins experts in global public health, infectious disease, and emergency preparedness have been at the forefront of the international response to COVID-19.
There Is No Timeline For Children Under 12
That authorization does not extend to children under the age of 12. FDA officials have acknowledged the interest in vaccination for children in that age group but were unable Monday to provide a timeline for a decision on use of the vaccine for those under 12.
“Currently there are still trials ongoing here,” Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, told reporters. “The agency has to wait for the companies to submit. … Obviously, we will move swiftly, but first the trials have to be finished … and the data need to be submitted to us.”
The FDA acted Monday without convening a customary public meeting of expert advisers to vet information about the vaccine and make recommendations to the regulator.
As part of the approval process, the vaccine also got a brand name: Comirnaty. The FDA says that’s pronounced “koe-mir’-na-tee.”
As of Sunday, 73% of adults in the U.S. have had at least one dose of the Pfizer, Moderna or Johnson & Johnson vaccines. Pfizer’s vaccine is most commonly administered, accounting for about 56% of the doses administered overall, according to data from the Centers for Disease Control and Prevention.
Moderna’s COVID-19 vaccine remains under the FDA’s review, but its approval is expected to follow in the near future.
Also Check: How Long Does A Rapid Covid Test Take
What About A Johnson & Johnson Booster
On Aug. 25, Johnson & Johnson said a booster shot of its COVID-19 vaccine increases antibody responses in those who received the company’s one-dose vaccine, based on interim data from an early trial. Biden administration health officials said they expect those who received the one-dose Johnson & Johnson vaccine will need another jab, but more research is necessary.;
The company said it would work with public health officials on a plan for a booster shot for eight months or longer after the first dose of its vaccine, but there is no time frame in place. Currently, the one-dose Johnson & Johnson vaccine is available under an emergency use authorization for individuals 18 years of age and older.